Tag: Linkers
What are the latest technologies being used to develop ADCs?
Targets
Most targets of ADC have unique requirements, including homogenous expression of ADC-accessible tumor surface antigens that internalize well and trafficked to lysosomes. Ideally the...
Linkers for Antibody Drug Conjugates: Current Role and Advancements
Advancements in research have shifted the way we think of combating cancer, and traditional treatment options are on the path to being replaced by...
A Chemistry Driven Approach to Uniform Antibody-drug Conjugates: New Data on...
Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics,
presented new data utilizing the company's SNAP site-specific ADC linker technology.
ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate
Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...
